Pharmafile Logo
Pharmafocus logo
Advanced Search

sobi

Showing 15 posts of 15 posts found.

Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases

January 28, 2026
Aspaveli, European Commission, Nephrology, sobi

Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) for the treatment of two …

News

Mavatar announces research collaboration with Sobi

January 6, 2026
Research and Development Immunology, Mavatar, Rare Diseases, sobi

Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology to generate data insights into …

News
hospital_ward

FDA approves Gamifant for macrophage activation syndrome in Still’s disease

June 30, 2025
Medical Communications, Research and Development FDA, Immunology, Still's disease, gamifant, hemophagocytic lymphohistiocytosis, sobi

The US Food and Drug Administration (FDA) has approved Gamifant (emapalumab-lzsg) for the treatment of macrophage activation syndrome (MAS) in …

News
blood-75301_640

Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia

April 28, 2025
Pharmacy sales & educational programmes, Sales and Marketing Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi

Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian …

News

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024
Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi

Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …

News

Sobi acquires CTI BioPharma Corporation for $1.7bn

May 10, 2023
Medical Communications CTI, acquisition, sobi

Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …

News

FDA approves first ever therapy for ultra rare primary haemophagocytic lymphohistiocytosis

November 21, 2018
Research and Development, Sales and Marketing FDA, Novimmune, pharma, sobi

The partnership of Sobi and Novimmune has revealed that their interferon gamma (IFNγ) blocking antibody Gamifant (emapalumab-lzsg) has received approval …

News
shutterstock_273326141

AstraZeneca sells off paediatric lung infection drug to Sobi for $1.5bn

November 13, 2018
Manufacturing and Production, Sales and Marketing AstraZeneca, Synagis, espiratory syncytial virus, pharma, sobi

AstraZeneca has jettisoned another non-essential asset with the sale of Synagis (palivizumab), a preventative treatment for infections relating to respiratory …

News
csm_packshot_kineret_814229b3fc

Sobi receives expanded EU approval for Kineret

April 11, 2018
Research and Development, Sales and Marketing Kineret, anti-inflammatory, biotech, drugs, pharma, pharmaceutical, sobi

Joining its current indication as a treatment for rheumatoid arthritis and cryopyrin-associated periodic syndromes, Sobi’s Kineret has been given approval …

News
sobi

Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder

June 15, 2016
Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi

Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …

News
biogen_logo

Sobi, Biogen’s haemophilia B therapy gets European approval

May 13, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi

Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …

News
sobi

Sobi profits rise as it rolls out haemophilia drug in Europe

April 28, 2016
Financial, Q1, earnings, results, revenue, sobi

Swedish Orphan Biovitrum (Sobi) (STO: SOBI) nearly doubled its first-quarter profit driven by immediate reimbursements from Germany. The company reported …

News
blood

Sobi launches new haemophilia treatment in UK

January 19, 2016
Manufacturing and Production, Sales and Marketing elocta, haemophilia a, sobi

Swedish Orphan Biovitrum Ltd (Sobi) has launched its haemophilia A treatment Elocta (efmoroctocog alfa) in the UK, following its EU …

News
Biogen image

Sobi and Biogen’s haemophilia A treatment EU-approved

November 27, 2015
Sales and Marketing Biogen, elocta, haemophilia a, sobi

Elocta, the haemophilia A treatment developed by the Swedish Orphan Biovitrum (Sobi) and Biogen, has received European Commission approval as …

News
Biogen image

EMA review for Biogen Idec’s haemophilia A therapy

November 4, 2014
Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi

The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026